The SLAS Technology Editor’s Top 10 for 2023 highlights technologies that address a broad range of unmet needs in both the laboratory and the clinic.
While it can take years for the pharmaceutical industry to create medicines capable of treating or curing human disease, a new study suggests that using generative artificial intelligence could vastly accelerate the drug-development process.
A ground-breaking study by Loughborough University and the University of Oxford has led to the development of a small molecule probe that could deepen our understanding of a crucial cellular messenger and lead to the development of new therapeutic drugs.
The risk of side effects can rise if drugs are taken for conditions other than Alzheimer's disease (AD) treatment. Some sedatives and antidepressants can deteriorate cognitive function, make people drowsy and confused, and worsen cognitive impairment, which increases the risk of falls.
Plasma engineers and chemists at the University of Illinois demonstrated a sustainable way of forming carbon-carbon bonds — the bedrock of all organic compounds — without expensive rare metals that are typically required as catalysts.
Breakthrough study addresses unmet need in the treatment of Crohn’s disease and helps patients into clinical and endoscopic remission
For patients undergoing total knee arthroplasty (TKA), a combination of intravenous and periarticular corticosteroids does not improve pain control – but, may improve key indicators of functional recovery in the days after surgery, reports a trial in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
In aerobic organisms, reactive oxygen species (ROS), such as hydroxide (OH), singlet oxygen (1O2), hydrogen peroxide (H2O2), and superoxide (O2–) ions are produced during aerobic respiration, which causes serious oxidative damage to biomolecules in the body.
In a noteworthy case study published in the Journal of Alzheimer’s Disease investigators report autopsy findings in a 65-year-old woman with Alzheimer’s disease (AD) who received three open label infusions of the experimental anti-amyloid beta (Aβ) antibody drug lecanemab.
Taking a daily multivitamin may help slow age-related memory decline, a study has found.
Chunyu Wang, Ph.D., professor of biological sciences at Rensselaer Polytechnic Institute, has added to his body of research on Alzheimer’s disease with significant findings in Angewandte Chemie.Together with his team, which includes first author and Rensselaer doctoral student Dylan Mah, Wang performed the most comprehensive study to date of the interactions between ApoE, or Apolipoprotein E, and heparan sulfate (HS).
Weed killers of the future could soon be based on failed antibiotics. A molecule which was initially developed to treat tuberculosis but failed to progress out of the lab as an antibiotic is now showing promise as a powerful foe for weeds that invade our gardens and cost farmers billions of dollars each year. While the failed antibiotic wasn’t fit for its original purpose, scientists at the University of Adelaide discovered that by tweaking its structure, the molecule became effective at killing two of the most problematic weeds in Australia, annual ryegrass and wild radish, without harming bacterial and human cells.
Chronic obstructive pulmonary disease patients newly prescribed non-benzodiazepine benzodiazepine receptor agonists (NBZRAs) such as zolpidem (Ambien, Intermezzo and other brands), a class of hypnotic drugs prescribed for insomnia, did not have an increased risk of exacerbations requiring hospitalizations or of death than those prescribed other types of hypnotics, according to research published at the ATS 2023 International Conference.
Meta, the parent company of Facebook and Instagram, was fined a record 1.2 billion euros ($1.3 billion) and ordered to stop transferring data collected from Facebook users in Europe to the United States. Find the latest research and expert commentary on privacy issues and controversial business practices in the Business Ethics channel.
The public are in favour of the development of bacteria-killing viruses as an alternative to antibiotics – and more efforts to educate will make them significantly more likely to use the treatment, a new study shows.
New guidelines for the management of chronic idiopathic constipation in adults are first to recommend magnesium oxide and senna as evidence-based treatments. This is a joint clinical practice guideline of the American College of Gastroenterology and the American Gastroenterological Association.
The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington’s disease, when compared to a placebo, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.
Since the start of the COVID-19 pandemic, a class of corticosteroids called glucocorticoids (GCs) have become established as one of the main treatment options, especially for severe cases, thanks to their anti-inflammatory and immunosuppressant action. Brazilian researchers recently discovered new ways in which these drugs influence the organism’s inflammatory response during an infection.
Researchers from Rice University have created drug-filled microparticles that can be engineered to degrade and release their therapeutic cargo days or weeks after administration. By combining multiple microparticles with different degradation times into a single injection, the researchers could develop a drug formulation that delivers many doses over time.
Skin cancer is the most prevalent form of cancer in the United States, with over 5 million cases diagnosed annually. The Centers for Disease Control and Prevention reports that melanoma alone accounts for more than 8,000 deaths each year. Thankfully, skin cancer is highly preventable, making it crucial to prioritize protection. Below are some of the latest headlines in the Dermatology channel.
For nearly 25 years, Dr. James Kirby has worked to advance the fight against infectious diseases by finding and developing new, potent antimicrobials, and by better understanding how disease-causing bacteria make us sick. In a recent paper published in PLOS Biology, Kirby and colleagues investigated a naturally occurring antimicrobial agent discovered more than 80 years ago.
An old antibiotic may provide much-needed protection against multi-drug resistant bacterial infections, according to a new study publishing May 16th in the open access journal PLOS Biology by James Kirby of Harvard Medical School, US, and colleagues.
Rutgers researcher leads test that validates a new weapon against antibiotic-resistant disease.
Dr. Sarah Prager looks at the impacts of recent federal court rulings on Washington state and nearby states, as well as the impact of rulings on miscarriage care.
In the medicine market, most newly introduced drugs and drug candidates show poor water solubility, which prevents their absorption in the body. This, in turn, limits their therapeutic efficiency.
Mobius Therapeutics™, LLC, a St. Louis-based perioperative ophthalmic pharmaceutical company, will initiate a series of professional education sessions, focused on how end users of Mitosol® can achieve compliance with USP <800>, the soon to be implemented and enforced standards for control of hazardous drugs in healthcare facilities.
The anti-dementia medication lecanemab and its ancillary costs could add $2 billion to $5 billion in annual Medicare spending if the Centers for Medicare and Medicaid Services (CMS) revise their coverage decision. Currently, the medication is covered only for patients who are enrolled in clinical trials.
May is Mental Health Awareness Month. Get your mental health news here.
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research published in The New England Journal of Medicine and led by an oncologist from Dana-Farber Cancer Institute.
Most antidepressants used for chronic pain are being prescribed with “insufficient” evidence of their effectiveness, scientists have warned.
A new advanced artificial intelligence (AI) system has shown world-leading accuracy and speed in identifying protein patterns within individual cells.
A new drug delivery system delivers an antioxidant directly to mitochondria in the liver, mitigating the effects of oxidative stress.
The U.S. Food and Drug Administration has approved Arexvy, the first RSV vaccine cleared for use in the United States. Arexvy has been in development for years, and is based on structural biology work done at the Advanced Photon Source between 2009 and 2013.
In this study, patients using medical cannabis reported improvements in health-related quality of life, which were mostly sustained over time. Adverse events were rarely serious but common, highlighting the need for caution with prescribing medical cannabis.
We’ve all recently gotten a crash-course in drug repurposing, thanks to near-daily news reports about efforts to identify existing medicines that could help treat COVID-19 in the early phase of the pandemic.
Many people have experienced infections from E. coli, which are primarily seen as inconvenient and unpleasant. For some patients, like those with blood cancer, however, there is a risk that the bacteria will travel into the bloodstream.
According to a new Johns Hopkins Medicine study, low pain self-efficacy can predict daily pre-surgery prescribed opioid use among patients seeking elective spine surgery.
Nucleus RadioPharma, a radiopharmaceutical company founded by Eclipse and Mayo Clinic, announced today it has received approval from the Minnesota Department of Employment and Economic Development (DEED) for its economic incentive request to support a facility in Rochester.
In a first-of-its-kind analysis, Cornell University researchers and partners found that pharmaceutical producers could reduce their environmental impact by roughly half by optimizing manufacturing processes and supply chain networks and by switching to renewable energy sources.
In a University of California, Irvine-led study, researchers have discovered small-molecule drugs with potential clinical utility in the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).
A recent clinical trial showed that the drug combination of cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer when compared with placebo plus platinum chemotherapy. Now an analysis published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society, indicates that cemiplimab plus platinum chemotherapy also affects quality of life compared to chemotherapy alone.
A sharp increase in the price of the gout drug colchicine, the result of an unusual FDA policy, led to lower use and poorer disease control. The findings have implications for other drugs, whose price could be similarly affected by government policies and manufacturer decisions.
Although the On-X aortic valve and apixaban have been approved for use by the U.S. Food and Drug Administration (FDA), they had not been approved to be used together. Between May 2020 and September 2022, the PROACT Xa randomized, multicenter, open-label trial compared the direct factor Xa inhibitor apixaban (Eliquis) with warfarin in patients with bileaflet carbon aortic valves.
The researcher discusses the findings in a new study on the efficacy and safety of fecal microbiota (REBYOTA™), the first microbiota-based live biotherapeutic approved by the US FDA used to prevent recurrent Clostridioides difficile infection in adults.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
